🇺🇸 FDA
Patent

US 10905770

Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

granted A61KA61K2039/505A61K31/047

Quick answer

US patent 10905770 (Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases) held by MacRegen, Inc. expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MacRegen, Inc.
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K31/047, A61K31/065, A61K31/366